Glenmark Pharmaceuticals has launched Empagliflozin, a widely recognized SGLT2 inhibitor, in India. The drug has been introduced under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)—Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg).
These medications are designed to improve glycemic control in adults with T2DM while also reducing cardiovascular outcomes in T2DM patients with CV risk.
Empagliflozin is a globally established treatment for HF, T2DM and T2DM with established cardiovascular disease (CVD), offering multiple benefits like cardiovascular and renal safety. The EMPA-REG clinical trial demonstrated a 14% reduction in major cardiovascular events, positioning Empagliflozin as a significant advancement in T2DM patients with high CV risks.